Welcome to our dedicated page for Nuvectis Pharma SEC filings (Ticker: NVCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing can feel like decoding genetics itself—especially when Nuvectis Pharma’s clinical trial data, cash-runway tables, and risk factors stretch past 200 pages. If you have ever typed “Nuvectis Pharma SEC filings explained simply� into a search bar, this page is built for you.
Stock Titan’s AI-powered summaries turn dense disclosures into clear takeaways. Need the latest numbers on R&D spend or trial enrollment? Our engine flags them inside every Nuvectis Pharma quarterly earnings report 10-Q filing and delivers real-time alerts the moment a new document hits EDGAR. You can dive into a Nuvectis Pharma annual report 10-K simplified for pipeline timelines, or compare quarter-over-quarter burn-rate trends through our “Nuvectis Pharma earnings report filing analysis� module. Each section links directly back to the source PDF so you can verify every figure without endless scrolling.
Monitoring management moves is equally direct. Follow Nuvectis Pharma insider trading Form 4 transactions and get push notifications for Nuvectis Pharma Form 4 insider transactions real-time. Our dashboards group every Nuvectis Pharma executive stock transactions Form 4 by officer, while AI annotations highlight correlations with clinical milestones disclosed in Nuvectis Pharma 8-K material events explained. Looking for governance details? The latest Nuvectis Pharma proxy statement executive compensation is parsed so you can see option grants and performance shares at a glance. In short, understanding Nuvectis Pharma SEC documents with AI is no longer a multi-day project—it’s a five-minute read supported by real-time data and expert context.
Form 4 Overview: On 06/20/2025, Charles Mosseri-Marlio, a 10% owner of Nuvectis Pharma, Inc. (NVCT), filed a Form 4 disclosing an open-market purchase of 5,603 shares of the company’s common stock at a price of $7.99 per share. The transaction was executed indirectly through Emerald Hill Ventures SARL SPF, an entity Mosseri-Marlio beneficially owns.
Following the purchase, the insider’s aggregate ownership rose to 2,981,806 shares held indirectly and 109,321 shares held directly. The filing lists transaction code "P," signifying a standard open-market purchase. No sales, derivative security activity, or 10b5-1 plan indications were reported.
The additional shares represent less than 0.2% of Mosseri-Marlio’s total reported holdings but still reflect continued alignment with public shareholders. The filing contains no operational updates or financial metrics beyond the share purchase details.
Key take-away: Nuvectis Pharma, Inc. (NVCT) filed a Form 4 showing that 10% owner Charles Mosseri-Marlio, via Emerald Hill Ventures SARL SPF, bought 33,442 common shares in two open-market transactions on 17-18 Jun 2025.
- Prices: weighted-average $8.11 on 17 Jun for 5,399 shares and $8.05 (range $7.91-$8.11) on 18 Jun for 28,043 shares.
- Post-purchase holdings: 2,976,203 shares held indirectly, up from 2,942,761.
- Transaction code “P� confirms open-market purchases; no 10b5-1 plan indicated.
- No derivative securities or sales reported; filing does not include earnings or operational metrics.
The estimated cash outlay is roughly $270k; insider accumulation at market prices often signals management’s confidence and can be viewed as a bullish indicator by investors. Because the investor already owns more than 10% of NVCT, the additional purchase marginally increases an already significant stake and reinforces alignment with minority shareholders.
FAQ
What is the current stock price of Nuvectis Pharma (NVCT)?
What is the market cap of Nuvectis Pharma (NVCT)?
